Literature DB >> 9389705

Heterogeneity in the breakpoints in balanced rearrangements involving band 12p13 in hematologic malignancies identified by fluorescence in situ hybridization: TEL (ETV6 ) is involved in only one half.

Y Sato1, S K Bohlander, H Kobayashi, S Reshmi, Y Suto, E M Davis, R Espinosa, R Hoopes, K T Montgomery, R S Kucherlapati, M M Le Beau, J D Rowley.   

Abstract

Using fluorescence in situ hybridization (FISH) and probes located on 12p12.1 to 13.3, we studied the breakpoints of 23 patients who had various hematologic malignant diseases and who had 12p13-balanced translocations (21 patients), inversion (1 patient), or insertion (1 patient). Among them, 14 patients had breakpoints within YAC964c10, which contains the TEL (ETV6 ) gene and in 12 of these with balanced translocations or insertion, the FISH results suggested that TEL was involved. Two of the 14 patients, patients no. 13 and 14, had breakpoints in YAC 964C10 that were centromeric to TEL but telomeric to KIP1. In the other 9 patients whose breakpoints did not fall within the YAC, the breakpoints were found telomeric to the YAC in at least three different locations on distal 12p. These results indicated that TEL was involved in only half (12 of 23) of the patients with balanced 12p13 rearrangements and that there probably were several other breakpoint cluster regions on 12p13, suggesting that genes other than TEL were involved in these rearrangements.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9389705

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  1 in total

1.  t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity.

Authors:  Sarah B Mueller; Paola Dal Cin; Long P Le; Dora Dias-Santagata; Jochen K Lennerz; A John Iafrate; Hetal Desai Marble; Andrew M Brunner; Matthew J Weinstock; Marlise R Luskin; Daniel J De Angelo; Richard M Stone; Valentina Nardi
Journal:  Blood Adv       Date:  2022-01-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.